A Retrospective Analysis of Intravenous Push versus Extended Infusion Meropenem in Critically Ill Patients

Meropenem is a broad-spectrum antibiotic used for the treatment of multi-drug-resistant infections. Due to its pharmacokinetic profile, meropenem's activity is optimized by maintaining a specific time the serum concentration remains above the minimum inhibitory concentration (MIC) via extended infusion (EI), continuous infusion, or intermittent infusion dosing strategies. The available literature varies regarding the superiority of these dosing strategies. This study's primary objective was to determine the difference in time to clinical stabilization between intravenous push (IVP) and EI administration. We performed a retrospective pilot cohort study of 100 critically ill patients who received meropenem by IVP (<i>n</i> = 50) or EI (<i>n</i> = 50) during their intensive care unit (ICU) admission. There was no statistically significant difference in the overall achievement of clinical stabilization between IVP and EI (48% vs. 44%, <i>p</i> = 0.17). However, the median time to clinical stability was shorter for the EI group (20.4 vs. 66.2 h, <i>p</i> = 0.01). EI administration was associated with shorter hospital (13 vs. 17 days; <i>p</i> = 0.05) and ICU (6 vs. 9 days; <i>p</i> = 0.02) lengths of stay. Although we did not find a statistically significant difference in the overall time to clinical stabilization, the results of this pilot study suggest that EI administration may produce quicker clinical resolutions than IVP.